MRI-Based Radiomic Fingerprint in Cervical Cancer: A New Predictor for Progression-Free Survival

Treatment response to definitive chemoradiation is variable among locally advanced cervical cancer patients with similar constellations of accepted prognostic features. Thus, patient outcomes are likely dependent on each patient's potentially unique cervix cancer habitat. Radiomic analysis provides a new class of prognostic cancer biomarkers for characterizing tumor habit and has shown promise in more accurately stratifying prognoses in patients for several tumor sites. A radiomics signature utilizing Magnetic Resonance Imaging (MRI) obtained during brachytherapy fractions and associated with patient outcomes has not yet been described. The Purpose of this study is to develop an axial T2 SPACE MRI-based radiomics signature as a prognostic tool to predict survival outcomes in cervical cancer.